[Skip to Content]
[Skip to Content Landing]
Views 395
Citations 0
Comment & Response
April 19, 2016

Efficacy of the Priority Review Voucher Program

Author Affiliations
  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;315(15):1660-1661. doi:10.1001/jama.2016.0386

In Reply We agree with Dr Ridley and colleagues that greater funding for the NIH is important to the discovery of transformative new treatments for tropical diseases.1 Indeed, substantial gains can be made with remarkably little up-front investment. For example, the Drugs for Neglected Diseases Initiative, which has been in existence only a few years longer than the tropical disease priority review voucher program, has spearheaded the development of 6 treatments (and early-stage testing of 12 new chemical entities) for patients with malaria, trypanosomiasis, visceral leishmaniasis, and Chagas disease at a total cost of around $250 million.2

First Page Preview View Large
First page PDF preview
First page PDF preview